$1760 | SAVE $240 | Single User
$3520 | SAVE $480 | Site License
$5280 | SAVE $720 | Enterprise License

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017
[Report Updated: 13-06-2017]

Published by Global Markets Direct: 13 Jun 2017 | 81534 | In Stock
Related Topics: Healthcare , Women's Health

Introduction

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline landscape.

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence. Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. Treatment includes topical (vaginal) estrogen and systemic estrogen therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 2 respectively.

Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017 [Report Updated: 13-06-2017]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Vaginal Atrophy (Atrophic Vaginitis) - Overview

    Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Products under Development by Companies

    Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development

    Allergan Plc

    Foamix Pharmaceuticals Ltd

    Mithra Pharmaceuticals SA

    PEPTONIC medical AB

    Sermonix Pharmaceuticals LLC

    TherapeuticsMD Inc

    Vaginal Atrophy (Atrophic Vaginitis) - Drug Profiles

    (estradiol + progesterone) - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Estetrol - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    estradiol hemihydrate - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    lasofoxifene tartrate - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    oxytocin - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    WC-3011 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects

    Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones

    Featured News & Press Releases

    Mar 01, 2017: Acerus Files a New Drug Submission for GYNOFLOR in Canada

    May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor

    Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study

    Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting

    Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting

    Jul 17, 2015: Last subject exits Peptonic Medical’s phase 2b VVA study

    Mar 23, 2015: Peptonic Medical’s formulation patent to be approved in the USA

    Mar 18, 2015: Patient recruitment to Peptonic Medical’s phase 2b study soon completed

    Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin

    Dec 01, 2014: Peptonic Medical’s formulation patent to be approved in Europe

    Oct 28, 2014: First patients included in Peptonic Medical AB’s clinical phase 2b study

    Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study

    Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study

    Mar 01, 2013: Peptonic Medical Receives New Formulation Patent For Vagitocin In Sweden

    Jan 05, 2012: Peptonic's Oxytocin Receives Approval For Dose-Finding Trial From Swedish Medical Products Agency

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

81534 | GMDHC9405IDB

Number of Pages

42

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Vaginal Cancer - Pipeline Review, H1 2017
Vaginal Cancer - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and He...
13 Jun 2017 by Global Markets Direct USD $1,760 (normally
USD $2,000)
More Info
SAVE 12% today! Global Vaginal Laxity Market: Size, Trends & Forecasts (2017-2021)
Scope of the ReportThe report titled “Global Vaginal Laxity Market: Size, Trends & Forecasts (2017-2...
01 Jun 2017 by Daedal Research USD $704 (normally
USD $800)
More Info
SAVE 12% today! Gynecological Devices Market: By Endoscope Types (Colposcopies, Laparoscopes, Resect scopes); By Devices (Vaginal Speculum, Examination Chairs, Cervical Dilators, Ablation and Fluid Management Devices and Others); By End Users (Hospitals, Clinics/ASCs, Research Institutes) & Geography Forecast (2017-2022)
Gynecological devices are extensively used in hospitals, clinics/ASCs, research institutes and diagn...
05 May 2017 by USD $4,620 (normally
USD $5,250)
More Info
SAVE 12% today! Topical Drug Delivery Market by Product Type (Formulation (Solid, Cream, Lotion, Paste, Liquid), Transdermal (Patch, Gel)), Route of Administration (Skin, Ophthalmic, Rectal, Vaginal, Nasal), & Facility of Use (Hospital, Clinic, Home care, Research) - Global Forecast to 2021
The global topical drug delivery market is poised to reach USD 125.88 billion by 2021 from USD 92.40...
27 Mar 2017 by MarketsandMarkets USD $4,972 (normally
USD $5,650)
More Info
SAVE 12% today! Vaginal Cancer Global Clinical Trials Review, H1, 2016
Vaginal Cancer Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Va...
19 May 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Vaginal Cancer Global Clinical Trials Review, H1, 2016
Vaginal Cancer Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Va...
19 May 2016 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! HPV Testing & Pap Test Market by Test Type (HPV Testing (Follow-Up, Co-Testing, Primary)), by Application (Pap Test (Cervical Cancer, Vaginal Cancer)), by End User (Laboratories, Hospitals, Physicians’ Offices & Clinics) - Global Forecast to 2020
Increasing awareness of cervical cancer screening programs, and government initiative and funding ar...
12 Feb 2016 by MarketsandMarkets USD $4,092 (normally
USD $4,650)
More Info
SAVE 12% today! Postmenopausal Vaginal Atrophy Global Clinical Trials Review, H2, 2015
Postmenopausal Vaginal Atrophy Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical t...
09 Dec 2015 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Vaginal Atrophy (Atrophic Vaginitis) Global Clinical Trials Review, H2, 2015
Vaginal Atrophy (Atrophic Vaginitis) Global Clinical Trials Review, H2, 2015SummaryGlobalData's clin...
04 Dec 2015 by Global Data USD $2,200 (normally
USD $2,500)
More Info
SAVE 12% today! Soft Tissue Repair Market by Product (Mesh/Tissue patch, Allograft, Xenograft, Suture Anchor, Interference Screws, Laparoscopic Instruments) by Application (Hernia, Dural, Orthopedic, Skin, Dental, Vaginal, Breast augmentation) - Global Forecast to 2019
Soft tissue repair products are used to repair and reconstruct soft tissue injuries. The soft tissue...
06 Mar 2015 by MarketsandMarkets USD $4,972 (normally
USD $5,650)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2017 [Report Updated: 13-06-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...